2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow brigatinib: new trials by email Literature Review of brigatinib trials Research Report on brigatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer Brigatinib, Alectinib - ALK+ Advanced NSCLC | Phase 3 | Completed | Takeda | 248 | 2019-04-19 | 2025-09-12 |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Brigatinib, Crizotinib - Non-small Cell Lung Cancer, Lung Cancer | Phase 3 | Completed | Ariad Pharmaceuticals | 275 | 2016-05-26 | 2021-08-20 |
Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Large Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Lung Neoplasms (1)
Ariad Pharmaceuticals (1) · Takeda (1)
Austria (2) · Canada (2) · France (2) · Germany (2) · Hong Kong (2) · Italy (2) · South Korea (2) · Spain (2) · Sweden (2) · Taiwan (2) · United States (2) · Argentina (1) · Australia (1) · Chile (1) · China (1)
PMID 28501139, PMID 30280657, PMID 32780660, PMID 34423676, PMID 37574132, PMID 39707229, PMID 41410381, PMID 41740899
2015 (1), 2018 (1)